The Patent Finder

Binding Molecules Specific for CD73 and Uses Thereof

MedImmune, LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 62/077,486, filed Nov 10, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,938,356Binding Molecules Specific for CD73 and Uses Thereof
In force
 · High confidence
MedImmune LimitedIn force
High confidence
US 10,287,362Binding Molecules Specific for CD73 and Uses Thereof
In force
 · High confidence
MedImmune LimitedIn force
High confidence
US 10,556,968Binding Molecules Specific for CD73 and Uses Thereof
In force
 · High confidence
MedImmune LimitedIn force
High confidence
US 11,525,012Binding Molecules Specific for CD73 and Uses Thereof
In force
 · High confidence
MedImmune LimitedIn force
High confidence
US 12,630,648Binding Molecules Specific for CD73 and Uses Thereof
In force
 · High confidence
MedImmune LimitedIn force
High confidence
Application 18/246,206Treatment Methods Using ANTI-CD73 and ANTI-PD-L1 Antibodies and Chemotherapy
Abandoned
Abandoned Jun 20, 2026
MedImmune, LLCAbandonedAbandoned Jun 20, 2026
Application 19/668,065Binding Molecules Specific for CD73 and Uses Thereof
Pending
Not granted
MedImmune LimitedPendingNot granted
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by MedImmune, LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited